Aller au contenu principal
Accès ouvert déclaré 2024 article

External validation of the Leiden Thrombosis Recurrence Risk Prediction models (L-TRRiP) for the prediction of recurrence after a first venous thrombosis in the Heart and Vascular Health study

2Citations signalées, ce qui n’est pas une note de qualité
4Institutions déclarées
2Pays d’affiliation déclarés

Rattachement africain : nl, us. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

Background: Long-term outcome after a first venous thromboembolism (VTE) might be optimized by tailoring anticoagulant treatment duration on individual risks of recurrence and major bleeding. The L-TRRiP models (A-D) were previously developed in data from the Dutch Multiple Environment and Genetic Assessment of Risk Factors for Venous thrombosis study to predict VTE recurrence. Objectives: We aimed to externally validate models C and D using data from the United States Heart and Vascular Health (HVH) study. Methods: Data from participants with a first VTE who discontinued initial anticoagulant therapy were used to determine model performance. Missing data were imputed, and results were pooled according to Rubin's rules. To determine discrimination, Harrell's C-statistic was calculated. To assess calibration, the observed/expected (O/E) ratio was estimated, and calibration plots were created, in which we accounted for the competing risk of death. A stratified analysis based on age <70 or >70 years was performed. Results: Of 1430 participants from the HVH study, 187 experienced an unprovoked VTE recurrence during follow-up. The C-statistics of L-TRRIP models C and D were 0.62 (95% CI, 0.56-0.67) and 0.61 (95% CI, 0.55-0.67), respectively. The O/E ratio (1.00; 95% CI, 0.84-1.17 and 1.09; 95% CI, 0.91-1.27, respectively) and calibration plots indicated good calibration. The discrimination was similar between participants <70 or >70 years, whereas overall calibration was lower in participants <70 years. Conclusion: The L-TRRiP models showed moderate discrimination and good calibration in a different population and can be used to guide clinical decision making. To assess the added value in daily clinical practice, a management study is needed.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
External validation of the Leiden Thrombosis Recurrence Risk Prediction models (L-TRRiP) for the prediction of recurrence after a first venous thrombosis in the Heart and Vascular Health study
Date Crossref
01/11/2024
Éditeur
Elsevier BV
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Où se fait cette recherche

  • Leiden University Medical Center Department of Clinical Epidemiology pays non établi dans la notice
    Organisme public
  • University of Washington Department of Medicine pays non établi dans la notice
    Université ou école supérieure
  • Kaiser Permanente Washington Health Research Institute pays non établi dans la notice
    Établissement de santé
  • VA Office of Research and Development pays non établi dans la notice
    Organisme public
  • Department of Veterans Affairs Office of Research and Development pays non établi dans la notice
    Institution

Department of Clinical Epidemiology — Leiden University Medical Center, Department of Medicine — University of Washington et Kaiser Permanente Washington Health Research Institute, avec 2 autres affiliations.

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Venous Thromboembolism Diagnosis and ManagementDiagnosis and Treatment of Venous DiseasesBlood Coagulation and Thrombosis Mechanisms

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.